Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Z, Tellier"'
Autor:
C. Rothschild, S. Claeyssens, Y. Gruel, Thierry Lambert, Z. Tellier, M.-H. André, N. Stieltjes, Claude Negrier, Pierre Sié, Jeanne-Yvonne Borg, A. Bertrand, L. Sanhes
Publikováno v:
Vox Sanguinis. 111:383-390
Background and Objectives A new fibrinogen concentrate Clottafact® was developed according to European guidelines on plasma-derived products. A post-authorization safety study was set up in 2009 as part of the risk management plan. This was a non-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::771c794d743c5d92a1291c4a9e26a5e4
https://doi.org/10.1111/vox.12424
https://doi.org/10.1111/vox.12424
Autor:
Vincent Piriou, Annie Borel-Derlon, A. Bertrand, J. Picard, Pierre Sié, Thierry Lambert, Y. Ozier, S. Claeyssens, E. de Maistre, Y. Gruel, M.-H. André, N. Stieltjes, Z. Tellier, A. Ducloy-Bouthors, François Fourrier, Claude Negrier, S. Boileau, Pascal Colson
Publikováno v:
Vox Sanguinis
Vox Sanguinis, Wiley, 2018, 113 (2), pp.120-127. ⟨10.1111/vox.12624⟩
Vox Sanguinis, Wiley, 2018, 113 (2), pp.120-127. ⟨10.1111/vox.12624⟩
International audience; BACKGROUND AND OBJECTIVES:A postauthorization safety study was performed between 2009 and 2012 to describe the use of Clottafact® in acquired fibrinogen deficiency in real-life medical practice in France.MATERIALS AND METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fb0104cdce5942b92e60d63e3a89a7f
https://hal.archives-ouvertes.fr/hal-01739807
https://hal.archives-ouvertes.fr/hal-01739807
Autor:
C, Négrier, A-S, Ducloy-Bouthors, V, Piriou, E, De Maistre, N, Stieltjes, A, Borel-Derlon, P, Colson, J, Picard, T, Lambert, S, Claeyssens, S, Boileau, A, Bertrand, M-H, André, F, Fourrier, Y, Ozier, P, Sié, Y, Gruel, Z, Tellier
Publikováno v:
Vox sanguinis. 113(2)
A postauthorization safety study was performed between 2009 and 2012 to describe the use of ClottafactOne hundred and fifty patients were planned for 28 days of prospective follow-up after infusion. The analysis of this observational study was descri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::06cf0e1b3f0d9ff8b07580bc594752fb
https://pubmed.ncbi.nlm.nih.gov/29238971
https://pubmed.ncbi.nlm.nih.gov/29238971
Publikováno v:
Vox Sanguinis. 103:35-41
Background and Objectives We studied the structural and functional properties of von Willebrand factor (VWF) molecules present in a very high-purity plasma-derived factor VIII concentrate (VHP pdFVIII – Factane®) because several observations sugge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d58878b055237590381b0eb28c360ce
https://doi.org/10.1111/j.1423-0410.2011.01576.x
https://doi.org/10.1111/j.1423-0410.2011.01576.x
Autor:
C, Négrier, C, Rothschild, J-Y, Borg, T, Lambert, S, Claeyssens, L, Sanhes, N, Stieltjes, A, Bertrand, M-H, André, P, Sié, Y, Gruel, Z, Tellier
Publikováno v:
Vox sanguinis. 111(4)
A new fibrinogen concentrate ClottafactThe analysis was descriptive and performed on 3 subgroups: prophylaxis vs. on-demand treatment, age (6,12 and ≥12) and severity of the deficiency.Fourteen patients [1-78 years] were included in 7 centres and f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7e0cd3720d73fbf5bea50b3caf855c62
https://pubmed.ncbi.nlm.nih.gov/27583698
https://pubmed.ncbi.nlm.nih.gov/27583698
Publikováno v:
Vox Sanguinis. 93:233-240
BACKGROUND/OBJECTIVES: A multicentre retrospective study was performed to assess the efficacy/safety of a French purified plasma-derived protein C (PC) concentrate in inherited PC deficiency. MATERIALS AND METHODS: Nine patients were enrolled, five c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b83fdb8affd8642c457f95667f4aed64
https://doi.org/10.1111/j.1423-0410.2007.00953.x
https://doi.org/10.1111/j.1423-0410.2007.00953.x
Autor:
Jenny Goudemand, Céline Henriet, Erik Berntorp, Françoise Bridey, P. M. Mannucci, Inge Scharrer, C. A. Lee, Chantal Rothschild, Z. Tellier, Annie Borel-Derlon, V. Roussel-Robert, Augusto B. Federici
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:1115-1124
Background and objectives: A plasma-derived von Willebrand factor (VWF) concentrate with low factor VIII (FVIII) content was specifically developed to treat von Willebrand disease (VWD). Efficacy and safety were investigated by merging the results of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a11b54b7889026d8caec1c582bb359ba
https://doi.org/10.1111/j.1538-7836.2007.02562.x
https://doi.org/10.1111/j.1538-7836.2007.02562.x
Autor:
Augusto B. Federici, Jenny Goudemand, Erik Berntorp, P. M. Mannucci, A. Borel-Derlon, Françoise Bridey, Claudine Caron, I. Scharrer, N. Stieltjes, C. A. Lee, Jean Michel Scherrmann, Z. Tellier
Publikováno v:
Journal of Thrombosis and Haemostasis. 3:2219-2227
Objective: In order to correct the primary von Willebrand factor (VWF) defect and avoid supra-physiologic plasma levels of factor VIII, a pure VWF concentrate almost devoid of FVIII was developed and used in France since 1989. Methods: The pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4788c13a2eb4509c17f136020d62bda9
https://doi.org/10.1111/j.1538-7836.2005.01435.x
https://doi.org/10.1111/j.1538-7836.2005.01435.x
Autor:
Z Tellier, Luc Mouthon
Publikováno v:
Transfusion Clinique et Biologique. 10:179-184
Intravenous Immunoglobulin (IVIg) provide a wide spectrum of antibody specificities in patients with antibody deficiencies and restore immune homeostasis in patients with auto-immune diseases. Controlled trials have now been performed in a large numb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b342e2729fda4373b946c0850dc275b5
https://doi.org/10.1016/s1246-7820(03)00043-0
https://doi.org/10.1016/s1246-7820(03)00043-0
Autor:
M Stagg, Franco Mandelli, Matthew Clarke, M. Mercier, R Alison, Françoise Huguet, Jean-Jacques Sotto, Z Tellier, Peter H. Wiernik, C Hicks, Keith Wheatley, A Tooth, Grp Amlc., V Evans, Richard Gray, Josy Reiffers, E Greaves, William R. Vogler, S James, D Wheatley, Susan M. Richards, Richard Peto, Emma Hall, V Polin, J P Dutcher, A. M. Stoppa, W R Bezwoda, M C Petti, Jean Luc Harousseau, E Berman, DA Sinclair
Publikováno v:
British Journal of Haematology. 103:100-109
A collaborative overview, using individual patient data, has been performed to compare idarubicin versus daunorubicin or other anthracyclines, when used with cytosine arabinoside as induction chemotherapy for newly diagnosed acute myeloid leukaemia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62197586116c7f7f5e274fa17ab1eba2
https://doi.org/10.1046/j.1365-2141.1998.00948.x
https://doi.org/10.1046/j.1365-2141.1998.00948.x